NCT00779285终止4 期
Cardiac Safety Profile of Caelyx Therapy in Anthracyclin Pretreated Metastatic Breast Cancer Patients.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 1
- 主要终点
- Cardiac Events
研究概览
简要总结
The purpose of this study is to evaluate the cardiac safety of Caelyx in patients with metastatic breast cancer who have previously received chemotherapy with anthracyclines.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women with histologically or cytologically confirmed metastatic breast cancer (no prior chemotherapy for metastatic disease).
- •Prior treatment with an anthracyclin-containing regimen in the adjuvant setting (cumulative dose >240mg/m^2 and <360mg/m^2 doxorubicin or >430mg/m^2 and <650mg/m^2 epirubicin).
- •Women >18 years of age.
- •Documented measurable and/or evaluable metastatic breast cancer by appropriate radiological imaging (computed tomography (CT) scan and/or magnetic resonance imaging (MRI)).
- •Performance status of at least 60% (Karnofsky index) and a life expectancy of at least 12 weeks.
- •Left ventricular ejection fraction >50%.
- •Normal organ function, except if abnormal due to tumor involvement.
- •Adequate bone marrow function as indicated:
- •Platelets >100,000/mm^3
- •Hemoglobin >9 g/dL
- •Neutrophils >1,500/mm^3
- •Adequate renal function as indicated by:
- •Serum Creatinine <1.5 x the upper limit of normal
- •Adequate liver function, as indicated by:
- •Bilirubin and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2 times upper limit of normal (<4 times upper limit of normal when related to primary disease)
- •Subjects must be capable to demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- •Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed intrauterine device (IUD), condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
- •Subjects must understand and be able to adhere to the dosing and visit schedules.
排除标准
- •Patient is pregnant or is breastfeeding.
- •Patients with moderate or severe heart failure (New York Heart Association (NYHA) class III/IV).
- •Hypersensitivity to anthracycline therapy or a history of severe hypersensitivity reactions to products containing Cremophor® EL (e.g., cyclosporin for injection concentrate and teniposide for injection concentrate).
- •Prior chemotherapy for metastatic disease.
- •Clinically significant hepatic disease (except liver metastases of primary disease).
- •Uncontrolled bacterial, viral, or fungal infection.
- •Radiotherapy in the last 4 weeks or prior radiation therapy to more than one-third of the hemopoietic sites.
- •Any other currently known malignancy or pre-malignant lesions or any history of other malignancy within the past five years (except non-melanoma skin cancer and surgically cured cervical cancer).
- •Symptomatic brain metastasis.
- •Patients who are incapacitated, largely or wholly bedridden or confined to a wheelchair, and who have little or no ability for self-care.
- •Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological or cerebral disease.
- •Documented human immunodeficiency virus (HIV) infection.
- •Any condition (medical, social, psychological) which would prevent adequate follow-up.
研究组 & 干预措施
Single-arm
Experimental
Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles
干预措施: Pegylated Liposomal Doxorubicin (Drug)
结局指标
主要结局
Cardiac Events
时间窗: Every 4 weeks during 6 cycles.
A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of \>=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of \>=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
不适用
Cardiac safety profile of Caelyx therapy in anthracyclin pretreated metastatic breast cancer patients.Women with histologically or cytologically confirmed metastatic breast cancer (no prior chemotherapy for metastatic disease).EUCTR2004-001177-25-HUSchering-Plough CE AG Hungarian Commercial Representative Office50
已完成
不适用
A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)Breast NeoplasmNCT00736333Merck Sharp & Dohme LLC167
已完成
2 期
A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)Breast NeoplasmNCT00687440Merck Sharp & Dohme LLC27
已完成
不适用
Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)Ovarian NeoplasmsNCT00743431Merck Sharp & Dohme LLC224
已完成
1 期
Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue SarcomaSarcomaNCT00030784European Organisation for Research and Treatment of Cancer - EORTC28